Search

Displaying results 781 - 790 of 4344 in total
  1. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … _ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by

  2. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335] … It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine.

  3. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]

  4. Drug

    Quinapril

    go.drugbank.com/drugs/DB00881
    ApprovedInvestigational

    Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat. It is used to treat hypertension and heart failure. ACE inhibitors are commonly used as a first line therapy in the treatment...

    Mixtures: ACCUZIDE 10MG/12.5MG, ACCUZIDE 20MG/12.5MGProducts: Accupril Tab 10mg, Accupril Tab 20mg
  5. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur ...

    Products: FYCOMPA FILM-COATED TABLET 10MG, Fycompa 10mg Film-coated Tablets
  6. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. … [A262681] It was granted approval by Health Canada in September 2010.[L49206]

    Products: APILEP® 50MG, BENVIDA 10MG/ML ŞURUP, 200 ML
  7. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    [A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. … [A255647,L44612] In March 2025, an extended-release formulation of diazoxide choline was approved by the FDA for the treatment of hyperphagia in patients with Prader-Willi syndrome, becoming the first

    Products: Proglycem Susp 50mg/ml
  8. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. … By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation.

    Products: Jakavi 20mg Tablets, Jakavi 10mg Tablets
  9. Drug

    Sparfloxacin

    go.drugbank.com/drugs/DB01208
    ApprovedWithdrawn

    Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.

  10. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).